Off-label use of intravenous immunoglobulin for recurrent spontaneous abortion a review of clinical effectiveness
Intravenous immunoglobulin (IVIG) has been identified as a potentially beneficial therapy for patients with recurrent spontaneous abortion (RSA); thus, this report aims to synthesize available evidence on the clinical effectiveness of off-label use of IVIG for RSA. This report is complementary to a...
| Main Authors: | , |
|---|---|
| Corporate Author: | |
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2018, May 2018
|
| Series: | CADTH rapid response report: summary with critical appraisal
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | Intravenous immunoglobulin (IVIG) has been identified as a potentially beneficial therapy for patients with recurrent spontaneous abortion (RSA); thus, this report aims to synthesize available evidence on the clinical effectiveness of off-label use of IVIG for RSA. This report is complementary to a 2017 CADTH Rapid Response, Summary of Abstracts report: "Off-Label Use of Intravenous Immunoglobulin for Solid Organ Transplant Rejection, Paraneoplastic Disorders, or Recurrent Miscarriage: Clinical Effectiveness" |
|---|---|
| Physical Description: | 1 PDF file (36 pages) |